Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
4.430
-0.110 (-2.42%)
At close: Jan 2, 2026, 4:00 PM EST
4.340
-0.090 (-2.03%)
After-hours: Jan 2, 2026, 7:17 PM EST
Nutriband Revenue
Nutriband had revenue of $346.06K in the quarter ending October 31, 2025, a decrease of -46.41%. This brings the company's revenue in the last twelve months to $2.28M, up 12.69% year-over-year. In the fiscal year ending January 31, 2025, Nutriband had annual revenue of $2.14M with 2.60% growth.
Revenue (ttm)
$2.28M
Revenue Growth
+12.69%
P/S Ratio
22.12
Revenue / Employee
$175,255
Employees
13
Market Cap
53.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
| Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
| Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
| Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
| Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
| Jan 31, 2020 | 370.65K | 125.36K | 51.11% |
| Jan 31, 2019 | 245.29K | - | - |
| Jan 31, 2018 | - | - | - |
| Jan 31, 2017 | - | - | - |
| Jan 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTRB News
- 2 days ago - Nutriband CEO Publishes Letter to Shareholders - GlobeNewsWire
- 4 days ago - Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio - GlobeNewsWire
- 15 days ago - Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction - GlobeNewsWire
- 5 weeks ago - Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference - Newsfile Corp
- 2 months ago - REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 2 months ago - Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 3 months ago - Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 3 months ago - Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology - GlobeNewsWire